Wolfgang G Kunz1, Myriam G Hunink1, Mohammed A Almekhlafi1, Bijoy K Menon1, Jeffrey L Saver1, Diederik W J Dippel1, Charles B L M Majoie1, Tudor G Jovin1, Antoni Davalos1, Serge Bracard1, Francis Guillemin1, Bruce C V Campbell1, Peter J Mitchell1, Philip White1, Keith W Muir1, Scott Brown1, Andrew M Demchuk1, Michael D Hill1, Mayank Goyal2. 1. From the University of Calgary (W.G.K., M.A.A., B.K.M., A.M.D., M.D.H., M.G.), Alberta, Canada; Department of Radiology (W.G.K.), University Hospital, LMU Munich, Germany; Harvard T.H. Chan School of Public Health (M.G.H.), Boston, MA; Erasmus MC (M.G.H., D.W.J.D.), University Medical Center Rotterdam, the Netherlands; Faculty of Medicine (M.A.A.), King Abdulaziz University, Jeddah, Saudi Arabia; David Geffen School of Medicine (J.L.S.), University of California-Los Angeles; Academic Medical Center (C.B.L.M.M.), Amsterdam, the Netherlands; University of Pittsburgh Medical Center (T.G.J.), PA; Hospital Germans Trias i Pujol (A.D.), Barcelona, Spain; University Hospital of Nancy (S. Bracard, F.G.), France; University of Melbourne (B.C.V.C., P.J.M.), Australia; Newcastle University (P.W.), UK; University of Glasgow (K.W.M.), UK; and Altair Biostatistics (S. Brown), St. Louis Park, MN. 2. From the University of Calgary (W.G.K., M.A.A., B.K.M., A.M.D., M.D.H., M.G.), Alberta, Canada; Department of Radiology (W.G.K.), University Hospital, LMU Munich, Germany; Harvard T.H. Chan School of Public Health (M.G.H.), Boston, MA; Erasmus MC (M.G.H., D.W.J.D.), University Medical Center Rotterdam, the Netherlands; Faculty of Medicine (M.A.A.), King Abdulaziz University, Jeddah, Saudi Arabia; David Geffen School of Medicine (J.L.S.), University of California-Los Angeles; Academic Medical Center (C.B.L.M.M.), Amsterdam, the Netherlands; University of Pittsburgh Medical Center (T.G.J.), PA; Hospital Germans Trias i Pujol (A.D.), Barcelona, Spain; University Hospital of Nancy (S. Bracard, F.G.), France; University of Melbourne (B.C.V.C., P.J.M.), Australia; Newcastle University (P.W.), UK; University of Glasgow (K.W.M.), UK; and Altair Biostatistics (S. Brown), St. Louis Park, MN. mgoyal@ucalgary.ca.
Abstract
OBJECTIVE: To determine public health and cost consequences of time delays to endovascular thrombectomy (EVT) for patients, health care systems, and society, we estimated quality-adjusted life-years (QALYs) of EVT-treated patients and associated costs based on times to treatment. METHODS: The Markov model analysis was performed from US health care and societal perspectives over a lifetime horizon. Contemporary data from 7 trials within the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration served as data source. Aside from cumulative lifetime costs, we calculated the net monetary benefit (NMB) to determine the economic value of care. We used a contemporary willingness-to-pay threshold of $100,000 per QALY for NMB calculations. RESULTS: Every 10 minutes of earlier treatment resulted in an average gain of 39 days (95% prediction interval 23-53 days) of disability-free life. Overall, the cumulative lifetime costs for patients with earlier or later treatment were similar. Patients with later treatment had higher morbidity-related costs but over a shorter time span due to their shorter life expectancy, resulting in similar lifetime costs as in patients with early treatment. Regarding the economic value of care, every 10 minutes of earlier treatment increased the NMB by $10,593 (95% prediction interval $5,549-$14,847) and by $10,915 (95% prediction interval $5,928-$15,356) taking health care and societal perspectives, respectively. CONCLUSIONS: Any time delay to EVT reduces QALYs and decreases the economic value of care provided by this intervention. Health care policies to implement efficient prehospital triage and to accelerate in-hospital workflow are urgently needed.
OBJECTIVE: To determine public health and cost consequences of time delays to endovascular thrombectomy (EVT) for patients, health care systems, and society, we estimated quality-adjusted life-years (QALYs) of EVT-treated patients and associated costs based on times to treatment. METHODS: The Markov model analysis was performed from US health care and societal perspectives over a lifetime horizon. Contemporary data from 7 trials within the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration served as data source. Aside from cumulative lifetime costs, we calculated the net monetary benefit (NMB) to determine the economic value of care. We used a contemporary willingness-to-pay threshold of $100,000 per QALY for NMB calculations. RESULTS: Every 10 minutes of earlier treatment resulted in an average gain of 39 days (95% prediction interval 23-53 days) of disability-free life. Overall, the cumulative lifetime costs for patients with earlier or later treatment were similar. Patients with later treatment had higher morbidity-related costs but over a shorter time span due to their shorter life expectancy, resulting in similar lifetime costs as in patients with early treatment. Regarding the economic value of care, every 10 minutes of earlier treatment increased the NMB by $10,593 (95% prediction interval $5,549-$14,847) and by $10,915 (95% prediction interval $5,928-$15,356) taking health care and societal perspectives, respectively. CONCLUSIONS: Any time delay to EVT reduces QALYs and decreases the economic value of care provided by this intervention. Health care policies to implement efficient prehospital triage and to accelerate in-hospital workflow are urgently needed.
Authors: Hooman Kamel; Neal S Parikh; Abhinaba Chatterjee; Luke K Kim; Jeffrey L Saver; Lee H Schwamm; Kori S Zachrison; Raul G Nogueira; Opeolu Adeoye; Iván Díaz; Andrew M Ryan; Ankur Pandya; Babak B Navi Journal: Stroke Date: 2021-05-13 Impact factor: 10.170
Authors: Alex Brehm; Ioannis Tsogkas; Johanna M Ospel; Christian Appenzeller-Herzog; Junya Aoki; Kazumi Kimura; Johannes A R Pfaff; Markus A Möhlenbruch; Manuel Requena; Marc J Ribo; Amrou Sarraj; Alejandro M Spiotta; Peter Sporns; Marios-Nikos Psychogios Journal: Ther Adv Neurol Disord Date: 2022-03-02 Impact factor: 6.570
Authors: Sushanth Rao Aroor; Kaiz S Asif; Jennifer Potter-Vig; Arun Sharma; Bijoy K Menon; Violiza Inoa; Cynthia B Zevallos; Jose G Romano; Santiago Ortega-Gutierrez; Larry B Goldstein; Dileep R Yavagal Journal: J Stroke Date: 2022-01-31 Impact factor: 6.967
Authors: Lazzaro di Biase; Adriano Bonura; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Vincenzo Di Lazzaro Journal: Ann Med Date: 2022-12 Impact factor: 5.348
Authors: Henk van Voorst; Wolfgang G Kunz; Lucie A van den Berg; Manon Kappelhof; Floor M E Pinckaers; Mayank Goyal; Myriam G M Hunink; Bart J Emmer; Maxim J H L Mulder; Diederik W J Dippel; Jonathan M Coutinho; Henk A Marquering; Hieronymus D Boogaarts; Aad van der Lugt; Wim H van Zwam; Yvo B W E M Roos; Erik Buskens; Marcel G W Dijkgraaf; Charles B L M Majoie Journal: J Neurointerv Surg Date: 2021-01-21 Impact factor: 5.836